Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Antiretroviral Drugs Market: By Drug Class, Non- Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrate Inhibitors, Fusion Inhibitors, Chemokine Receptor Inhibitors, Others), By Administration, By Distribution Channel, and Region Forecast 2019-2030
Antiretroviral Drugs Market size was valued at US$ 63.9 billion in 2023 and is poised to grow at a CAGR of 4.9% from 2024-2030. Cytopathic effects in cells in the brain and infected T cells may develop immune deficiencies and neurological diseases induced by HIV and related lentiviruses. Retrovirus causes immunological diseases including HIV and T-cell leukemia. Acquired immune deficiency syndrome (AIDS) is caused by the retrovirus known as human immunodeficiency virus (HIV) and T-Cell leukaemia caused by human T lymphotropic virus (HTLV). Antiretroviral drugs are the drugs that act or inhibit certain processes in viral replication and inhibit further worsening of the diseases. Globally antiviral drugs market is driven by increased cases of retroviral infections such as especially HIV/AIDS.
According to WHO, 36.7 million people were diagnosed with HIV/AIDS in 2015, whereas, 1.1 million people died of AIDS-related illness in the same year. The higher prevalence of HIV owing to various factors such as lack of availability of medication for the treatment of HIV infection, promising pipeline drugs, and increased funding by the government are expected to bolster the market over the forecast period. However, high costs of R&D and stringent regulatory procedures hamper the Market.
Furthermore, the availability of generic versions of blockbuster drugs affects the market revenue of antiretroviral drugs. The market is expected to grow at significant rates during the forecasting period owing to pipeline drugs such as etravirine (Merck & Co.), fostemsavir (Bristol-Myers Squibb), rilpivirine (Tibotec), etc. Market players are adopting strategies like mergers and acquisitions to improve their market share.
Study Period
2024-2030Base Year
2023CAGR
4.9%Largest Market
North AmericaFastest Growing Market
Asia Pacific
However, as viral illnesses such as HIV, Herpes, Influenza, and others become more common, demand for antiviral drugs is likely to rise over the forecast period. According to UNAIDS, more than 37 million people around the world would be living with HIV by 2020. In 2020, around 1.5 million more people will have contracted HIV. Overall, the COVID-19 pandemic has greatly improved market growth in 2020, however the pandemic has had a negative influence on other antiviral drug applications. Over the predicted period, a primary element driving demand for antiviral medications is the rising incidence of viral illness over the world.
According to the WHO, an estimated 325 million individuals worldwide have hepatitis, with 71 million of these having chronic hepatitis C virus infection. Furthermore, the United States Department of Health and Human Services estimates that 2.4 million people in the country have hepatitis C, with roughly 850,000 people infected with hepatitis B. The global need for antiviral medications is expected to rise as the number of patients grows.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 63.9 billion |
Market CAGR |
4.9% |
By Drug Class |
|
By Administration |
|
By Distribution channel |
|
Download Free Sample Report
The global antiretroviral drugs market size was valued at US$ 63.9 billion in 2023 and is projected to grow at a CAGR of 4.9% from 2024 to 2030.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
The antiretroviral drugs market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
1. Executive Summary |
2. Global Antiretroviral Drugs Market Introduction |
2.1.Global Antiretroviral Drugs Market - Taxonomy |
2.2.Global Antiretroviral Drugs Market - Definitions |
2.2.1.Drug Class |
2.2.2.Administration |
2.2.3. Distribution channel |
2.2.4.Region |
3. Global Antiretroviral Drugs Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID-19 on Market |
4. Global Antiretroviral Drugs Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Antiretroviral Drugs Market By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Nucleoside Reverse Transcriptase Inhibitors (NRT?s) |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT?s) |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Protease Inhibitors |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Integrate Inhibitors |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Fusion Inhibitors |
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Chemokine Receptor Inhibitors |
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
5.7. Others |
5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.7.3. Market Opportunity Analysis |
6. Global Antiretroviral Drugs Market By Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Oral |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Parenteral |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7. Global Antiretroviral Drugs Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Hospital Pharmacies |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail Pharmacies |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Online Pharmacies |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Others |
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
8. Global Antiretroviral Drugs Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9. North America Antiretroviral Drugs Market,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Nucleoside Reverse Transcriptase Inhibitors (NRT?s) |
9.1.2.Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT?s) |
9.1.3.Protease Inhibitors |
9.1.4.Integrate Inhibitors |
9.1.5.Fusion Inhibitors |
9.1.6.Chemokine Receptor Inhibitors |
9.1.7.Others |
9.2. Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Oral |
9.2.2.Parenteral |
9.3. Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospital Pharmacies |
9.3.2.Retail Pharmacies |
9.3.3.Online Pharmacies |
9.3.4.Others |
9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10. Europe Antiretroviral Drugs Market,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Nucleoside Reverse Transcriptase Inhibitors (NRT?s) |
10.1.2.Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT?s) |
10.1.3.Protease Inhibitors |
10.1.4.Integrate Inhibitors |
10.1.5.Fusion Inhibitors |
10.1.6.Chemokine Receptor Inhibitors |
10.1.7.Others |
10.2. Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Oral |
10.2.2.Parenteral |
10.3. Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospital Pharmacies |
10.3.2.Retail Pharmacies |
10.3.3.Online Pharmacies |
10.3.4.Others |
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
10.4.6.Rest of EU |
11. Asia Pacific (APAC) Antiretroviral Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Nucleoside Reverse Transcriptase Inhibitors (NRT?s) |
11.1.2.Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT?s) |
11.1.3.Protease Inhibitors |
11.1.4.Integrate Inhibitors |
11.1.5.Fusion Inhibitors |
11.1.6.Chemokine Receptor Inhibitors |
11.1.7.Others |
11.2. Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Oral |
11.2.2.Parenteral |
11.3. Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospital Pharmacies |
11.3.2.Retail Pharmacies |
11.3.3.Online Pharmacies |
11.3.4.Others |
11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12. Middle East and Africa (MEA) Antiretroviral Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Nucleoside Reverse Transcriptase Inhibitors (NRT?s) |
12.1.2.Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT?s) |
12.1.3.Protease Inhibitors |
12.1.4.Integrate Inhibitors |
12.1.5.Fusion Inhibitors |
12.1.6.Chemokine Receptor Inhibitors |
12.1.7.Others |
12.2. Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Oral |
12.2.2.Parenteral |
12.3. Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospital Pharmacies |
12.3.2.Retail Pharmacies |
12.3.3.Online Pharmacies |
12.3.4.Others |
12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13. Latin America Antiretroviral Drugs Market,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Nucleoside Reverse Transcriptase Inhibitors (NRT?s) |
13.1.2.Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT?s) |
13.1.3.Protease Inhibitors |
13.1.4.Integrate Inhibitors |
13.1.5.Fusion Inhibitors |
13.1.6.Chemokine Receptor Inhibitors |
13.1.7.Others |
13.2. Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Oral |
13.2.2.Parenteral |
13.3. Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospital Pharmacies |
13.3.2.Retail Pharmacies |
13.3.3.Online Pharmacies |
13.3.4.Others |
13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.F. Hoffmann-La Roche Ltd. |
14.2.2.GlaxoSmithKline plc |
14.2.3.AbbVie |
14.2.4.Merck & Co., Inc. |
14.2.5.Johnson & Johnson Services, Inc. |
14.2.6.Bristol-Myers Squibb Company |
14.2.7.Cipla Inc. |
14.2.8.Aurobindo Pharma |
14.2.9.Dr. Reddy?s Laboratories Ltd. |
15. Research Methodology |
Key Market Players